Jinling Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Jinling Pharmaceutical Co Ltd cash flow-to-debt ratio. Jinling Pharmaceutical Co Ltd (000919) has a Cash Flow-to-Debt Ratio of 0.06x as of September 2025, meaning its operating cash flow of CN¥74.01 Million could theoretically repay 0% of its total liabilities (CN¥1.18 Billion) in one year. Check how high is Jinling Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jinling Pharmaceutical Co Ltd (1999–2024)
Cash flow-to-debt ratio of Jinling Pharmaceutical Co Ltd from 1999 to 2024. Historical debt coverage capacity for Jinling Pharmaceutical Co Ltd across 26 annual periods. Check Jinling Pharmaceutical Co Ltd (000919) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Jinling Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (1999–2024)
Jinling Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 1999 to 2024. Year-by-year debt coverage analysis for Jinling Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Jinling Pharmaceutical Co Ltd cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.12x | CN¥154.19 Million | CN¥1.24 Billion | ▼ -32.3% |
| 2023 | 0.18x | CN¥158.92 Million | CN¥865.58 Million | ▼ -35.4% |
| 2022 | 0.28x | CN¥260.59 Million | CN¥916.30 Million | ▼ -11.1% |
| 2021 | 0.32x | CN¥292.03 Million | CN¥913.10 Million | ▼ -12.7% |
| 2020 | 0.37x | CN¥311.46 Million | CN¥850.43 Million | ▼ -42.3% |
| 2019 | 0.63x | CN¥465.85 Million | CN¥733.62 Million | ▼ -6.5% |
| 2018 | 0.68x | CN¥433.83 Million | CN¥638.90 Million | ▲ +23.1% |
| 2017 | 0.55x | CN¥443.11 Million | CN¥803.11 Million | ▲ +361.9% |
| 2016 | 0.12x | CN¥96.15 Million | CN¥804.90 Million | ▼ -47.9% |
| 2015 | 0.23x | CN¥212.45 Million | CN¥925.73 Million | ▼ -33.3% |
| 2014 | 0.34x | CN¥299.89 Million | CN¥871.24 Million | ▼ -7.4% |
| 2013 | 0.37x | CN¥271.21 Million | CN¥729.94 Million | ▲ +17.4% |
| 2012 | 0.32x | CN¥232.12 Million | CN¥733.12 Million | ▲ +16.0% |
| 2011 | 0.27x | CN¥172.82 Million | CN¥633.01 Million | ▼ -16.4% |
| 2010 | 0.33x | CN¥177.81 Million | CN¥544.47 Million | ▼ -30.6% |
| 2009 | 0.47x | CN¥188.41 Million | CN¥400.59 Million | ▼ -50.0% |
| 2008 | 0.94x | CN¥305.26 Million | CN¥324.25 Million | ▲ +232.4% |
| 2007 | 0.28x | CN¥118.06 Million | CN¥416.86 Million | ▼ -32.4% |
| 2006 | 0.42x | CN¥138.50 Million | CN¥330.39 Million | ▲ +7.6% |
| 2005 | 0.39x | CN¥109.29 Million | CN¥280.42 Million | ▼ -21.3% |
| 2004 | 0.50x | CN¥159.81 Million | CN¥322.83 Million | ▼ -21.7% |
| 2003 | 0.63x | CN¥161.86 Million | CN¥256.06 Million | ▲ +43.9% |
| 2002 | 0.44x | CN¥130.36 Million | CN¥296.79 Million | ▲ +45.6% |
| 2001 | 0.30x | CN¥92.49 Million | CN¥306.54 Million | ▼ -79.0% |
| 2000 | 1.43x | CN¥231.31 Million | CN¥161.37 Million | ▲ +452.4% |
| 1999 | 0.26x | CN¥39.77 Million | CN¥153.24 Million | — |